08:00 , Feb 21, 2011 |  BC Week In Review  |  Financial News

Biotec Pharmacon completes private placement

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway   Business: Dermatology, Cancer, Other   Date completed: 2/11/11   Type: Private placement   Raised: NOK7.6 million ($1.3 million)   Shares: 1.2 million   Price: NOK6.30   Shares after...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Company News

Biotec Pharmacon dermatology news

Biotec Pharmacon said that pending board approval it will focus on the development of its SBG as a medical device instead of a therapeutic to treat diabetic foot ulcers. The company also said it plans...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Financial News

Biotec Pharmacon completes private placement

Biotec Pharmacon ASA (OSE: BIOTEC), Tromso, Norway   Business: Dermatology, Cancer, Other   Date completed: 12/23/10   Type: Private placement   Raised: NOK22.1 million ($3.7 million)   Shares: 3.5 million   Price: NOK6.30   Shares...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Financial News

Biotec Pharmacon proposes private placement

Biotec Pharmacon ASA (OSE: BIOTEC), Tromso, Norway   Business: Dermatology, Cancer, Other   Date announced: 12/23/10   Type: Private placement   To be raised: Up to NOK7.6 million ($1.3 million)   Shares: 1.2 million  ...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Biotec Pharmacon preclinical data

In diabetic mice, SBG stored in polycarbonate containers significantly improved wound closure vs. both untreated and vehicle-treated control wounds, whereas SBG stored in polyethylene containers that were used in Phase III testing non-significantly improved wound...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Company News

Biotec Pharmacon management update

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway   Business: Dermatology, Cancer, Other   Hired: Svein Lien as CEO, formerly CEO of Axis-Shield plc ; he replaces Lars Viksmoen, who resigned  ...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Clinical News

SBG: Additional Phase III data

Biotec Pharmacon reported in its earnings that an unexpected interaction between SBG and polyethylene in the product containers may have rendered SBG inactive in Phase III studies. The company said it plans to conduct accelerated...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

Biotec Pharmacon, Sana Pharma A/S deal

Biotec Pharmacon sold its Immunocorp Consumer Health A/S subsidiary to supplement company Sana for NOK31.5 million ($5.5 million). Immunocorp markets dietary supplements and had revenues of NOK22 million ($3.8 million) for the nine months ended...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Company News

Biotec Pharmacon management update

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway   Business: Dermatology, Cancer, Other   Transitioned: Arvid Vangen, VP of finance and administration, and Lars Viksmoen, CEO, to share CFO duties  ...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to 34 $34.6 2.60 9/30/09 $10.0 Cuts primarily in R&D;...